Pancragen vs Melanotan 1
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
PancragenSkin & CosmeticSexual Health & Libido
Melanotan 1- Summary
- Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
- Melanotan 1 (Afamelanotide) is a synthetic analog of α-MSH that selectively stimulates melanogenesis (tanning) through MC1R activation. It provides UV-independent skin pigmentation and is FDA/EMA-approved under the name SCENESSE for erythropoietic protoporphyria (EPP) and vitiligo.
- Half-Life
- Short (minutes); sustained gene-regulatory effects
- ~40–60 minutes (free peptide); implant formulation (SCENESSE) releases over months
- Admin Route
- SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 0.5–1 mg
- Frequency
- Daily for 10–30 days
- Daily until desired color achieved, then maintenance
- Key Benefits
- Supports pancreatic beta cell function and insulin secretion
- May improve glucose metabolism in early metabolic dysfunction
- Protective effects on exocrine pancreatic tissue
- Anti-aging effects on pancreatic cells
- Potential support in type 2 diabetes management alongside standard care
- Reduces pancreatic cellular apoptosis from metabolic stress
- Complementary to GLP-1 agonists in metabolic protocols
- Induces skin pigmentation/tanning without UV exposure
- Provides photoprotection in photosensitivity conditions (EPP)
- FDA-approved for erythropoietic protoporphyria (SCENESSE)
- Approved in EU for EPP treatment
- Anti-inflammatory via MC1R
- Mild libido enhancement
- Potential skin cancer prevention through melanin protection
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant hypoglycemic events reported at standard doses as monotherapy
- Nausea (especially at higher doses)
- Facial flushing
- Fatigue
- Injection site reactions
- +3 more
- Stacks With
- —
- —